Latest news with #PRISM
Yahoo
11-07-2025
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Wave Life Sciences (WVE), Keeps the PT at $24
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 4, analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE), retaining the price target of $24.00. A biotechnology laboratory filled with computers and equipment to support research. The analyst supported the rating with the company's promising developments in RNA editing, especially in the treatment for alpha-1-antitrypsin deficiency (AATD). He reasoned that the initial human data for the company's WVE-006 compound exhibited optimistic results, as patients reached notable levels of AAT protein after a single low dose. According to Schwartz, this breakthrough marks a significant milestone for Wave Life Sciences Ltd. (NASDAQ:WVE) while also setting a precedent for the broader RNA editing domain. He expects the upcoming data readouts to have further positive outcomes and anticipates a dose-dependent rise in efficacy with an increase in dosage. The analyst also stated that the potential to exceed the established 11 µM threshold for AAT protein, and even approach normal healthy levels, may cause a considerable boost to the stock's value. Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that develops and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. PRISM combines a deep understanding of human genetics with chemistry innovation and multiple modalities for scientific discoveries and breakthroughs that treat prevalent and rare disorders. While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Business Wire
08-07-2025
- Health
- Business Wire
BostonGene Announces Collaboration with SWOG Cancer Research Network to Drive Personalized Approaches
WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced a collaboration with the SWOG Cancer Research Network, a global cancer research community that designs and conducts publicly funded clinical trials, on a new multicohort study titled " S2409, PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)." This study, which is supported by the National Cancer Institute (NCI), part of the National Institutes of Health, aims to redefine the standard of care for patients with ES-SCLC by employing biomarker-driven personalized treatment strategies. 'By combining advanced molecular profiling with AI, we're not only able to classify patients more precisely but also to advance therapy selection and accelerate the development of next-generation treatments." Currently, the standard treatment for ES-SCLC involves combination chemotherapy and anti-PD-L1 immunotherapy, followed by maintenance immunotherapy. While this broad approach extends overall survival by 2-3 months, it still results in disease progression in most patients. The PRISM study is designed to utilize novel biomarkers to identify and treat patients who may benefit from the addition of targeted agents, such as PARP inhibitors, to standard therapy. The study will be led by SWOG, conducted within the NCI's National Clinical Trials Network, and chaired by Drs. Anne Chiang, of the Yale Cancer Center, and Alberto Chiappori, of the Moffitt Cancer Center, in conjunction with Translational Medicine chairs Drs. Lauren Byers and Carl Gay, of The University of Texas MD Anderson Cancer Center. The trial will enroll up to 900 patients and use BostonGene's AI-powered multiomic platform to identify molecular subtypes, assigning patients to therapy based on their subtype. The platform enables deep characterization of each patient's tumor and immune profile, supporting the selection of more effective therapies and helping to accelerate translational insights that inform future drug development. The trial builds on the ongoing collaborative work between MD Anderson's lung cancer group, including Drs. Byers and Gay, and BostonGene to identify and validate four molecular subtypes of SCLC that exhibit distinct biological and therapeutic profiles. Initial findings from the SWOG S1929 trial demonstrated promising improvements in progression-free survival using this targeted approach. The goal of the upcoming study is to optimize outcomes for each subtype, offering patients more effective and individualized treatments. 'S2409 PRISM will test the hypothesis that we can be more effective in treating extensive-stage small-cell lung cancer by targeting the vulnerabilities of specific molecular subtypes,' said study chair Dr. Chiang, who also serves as SWOG's executive officer overseeing lung cancer and breast cancer research. 'We hope to demonstrate that it's feasible to identify the SCLC subtype in the clinical setting and to use that information to select the best therapy for each patient.' 'Collaborating with SWOG on this landmark study aligns with our mission to deliver innovative, data-driven insights that are transforming cancer care,' said Nathan Fowler, MD, Chief Medical Officer at BostonGene. 'By combining advanced molecular profiling with AI, we're not only able to classify patients more precisely but also to advance therapy selection and accelerate the development of next-generation treatments. This study is poised to reshape the treatment landscape in lung cancer and provide a roadmap of how to build and validate biomarker-driven treatment approaches across cancers.' About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit
Business Wire
07-07-2025
- Business
- Business Wire
Mitsubishi Electric's ME Innovation Fund Invests in AI-assisted PLM Systems Startup 'Things'
TOKYO--(BUSINESS WIRE)-- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Things, Inc., a Japan-based startup that develops and provides AI-assisted product lifecycle management (PLM) systems for manufacturing, specializing in comprehensive document management from product planning to development to disposal. This is the twelfth investment that the fund has made to date. Through this investment, Mitsubishi Electric aims to integrate its extensive manufacturing and control expertise with Things' generative AI technology to accelerate the development of digital transformation (DX) solutions that address various manufacturing challenges. In recent years, Japan's manufacturing industry has faced labor shortages, the aging of skilled technicians and other challenges that are inhibiting skills transfer. In response, DX initiatives such as the implementation of PLM and other digital systems have advanced rapidly, but have encountered issues regarding development time, cost, usability and scalability. Things introduced its 'PRISM' PLM system in May 2023 to leverage generative AI to improve the structure and usage of information in manufacturing. PRISM offers significant cost and scalability advantages for enhancing user interfaces and experiences, and for effectively implementing proofs of concept (PoCs) across a wide range of companies.
Yahoo
30-06-2025
- Business
- Yahoo
The Top 5 Analyst Questions From Nova's Q1 Earnings Call
Nova's first quarter results surpassed Wall Street's expectations, driven by robust demand from both logic and memory semiconductor manufacturers. Management attributed this outperformance to increased adoption of advanced process control solutions, particularly for gate-all-around and advanced packaging technologies. CEO Gaby Waisman pointed to record sales of the PRISM platform and a significant expansion in the company's software and services businesses. Waisman stated, 'Our performance was driven by Nova's strong standing across market segments, regions, key customers, and technologies.' Despite these results, management acknowledged that macroeconomic uncertainty and evolving trade dynamics are starting to influence operational visibility. Is now the time to buy NVMI? Find out in our full research report (it's free). Revenue: $213.4 million vs analyst estimates of $210.2 million (50.5% year-on-year growth, 1.5% beat) Adjusted EPS: $2.18 vs analyst estimates of $2.09 (4.4% beat) Adjusted EBITDA: $76.72 million vs analyst estimates of $73.62 million (36% margin, 4.2% beat) Revenue Guidance for Q2 CY2025 is $215 million at the midpoint, above analyst estimates of $211.7 million Adjusted EPS guidance for Q2 CY2025 is $2.05 at the midpoint, below analyst estimates of $2.10 Operating Margin: 29.6%, up from 26.2% in the same quarter last year Inventory Days Outstanding: 177, up from 168 in the previous quarter Market Capitalization: $7.87 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Ezra Weener (Jefferies) asked about the trajectory of gate-all-around revenue growth and its transition from pilot to high-volume manufacturing. CEO Gaby Waisman indicated the ramp is progressing as planned and expects business from this segment to be higher next year. Atif Malik (Citi) probed the degree of cross-selling between advanced packaging and gate-all-around customers. Waisman described double-digit growth in advanced packaging and highlighted Sentronics' contribution to this market segment. Atif Malik (Citi) followed up on the impact of tariffs on revenue in China and on service growth. CFO Guy Kizner confirmed that tariffs primarily affect gross margin, not revenue, and reiterated service growth targets of 10-15% for the year. Mark Lipacis (Evercore) sought clarification on the nature and geographic source of tariff impacts. Kizner explained that tariffs mainly affect the bill of materials and spare parts shipped between regions, due to Nova's mostly localized supply chain. Charles Shi (Needham & Company) questioned Nova's outlook for China and visibility into the second half of the year. Waisman said China revenue is expected to be flat or slightly down, but highlighted backlog strength and offsetting growth elsewhere. In coming quarters, the StockStory team will closely watch (1) whether Nova's advanced node and packaging solutions continue to gain market share, (2) how effectively the company manages margin headwinds from tariffs and supply chain shifts, and (3) progress on integrating Sentronics and expanding direct sales in Europe. The evolution of demand from China and customer investment in AI-related manufacturing will also be important signposts. Nova currently trades at $277, up from $201.53 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
United News of India
26-06-2025
- Politics
- United News of India
Two inactive political outfits in Mizoram face possible d)eregistration by ECI
Aizawl, June 26 (UNI) The Election Commission of India's ongoing scrutiny of dormant political outfits has placed two Mizoram-based registered unrecognised political parties at risk of being struck off the rolls, state election department officials said today. Out of the four Registered Unrecognised Political Parties (RUPPs) listed from Mizoram—Mizoram People's Conference (MPC), Hmar People's Convention (HPC), Mara Democratic Front (MDF), and the People's Representation for Identity and Status of Mizoram (PRISM) — two have failed to establish their operational status. Election officials confirmed that MDF and PRISM could not be located or verified during the most recent compliance review, putting them at the risk of losing their registration. The review comes in the wake of a major clean-up drive initiated by the ECI under Chief Election Commissioner Gyanesh Kumar and fellow Election Commissioners Dr. Sukbhir Singh Sandhu and Dr. Vivek Joshi. A press statement issued by the Chief Electoral Officer (CEO) of Mizoram noted that the ECI has identified 345 RUPPs across various states and Union Territories for non-compliance. These parties have neither participated in any election — Lok Sabha or state assemblies — since 2019, nor maintained valid office addresses. The Election Commission, through a nationwide verification effort, found that a significant number of the over 2,800 RUPPs on its records are no longer functioning as political entities. Many have not only failed to contest elections but also appear to lack physical presence or organisational structure. To ensure procedural fairness, the ECI has directed Chief Electoral Officers of all states and UTs to issue show-cause notices to the 345 defaulting RUPPs. These parties have been given an opportunity to respond before any final action is taken. The commission will decide on deregistration following this phase of explanation and verification, the press note stated. Under Section 29A of the Representation of the People Act, 1951, political parties—whether national, state or unrecognised—must register with the ECI in order to gain official status and qualify for various entitlements, including income tax exemptions. The press note added that only parties maintaining a minimal level of political activity and transparency should continue to enjoy these privileges. In Mizoram's context, the likely loss of registration by MDF and PRISM would mark the end of their official political journey, unless they can provide credible proof of continued activity. The ECI's move signals a tightening of standards in India's electoral landscape, aiming to uphold a more accountable and streamlined political registry. UNI XC SSP
